Skip to main content.

Clinical Trials

The following clinical trials are currently recruiting participants. If you would like more information regarding the trial or how to participate, please contact the study coordinator.

Trial Name Sponsor Summary Details Study Coordinator
FIND-CKD Bayer Phase 3 Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD). Participants will take finerenone or a placebo once a day as tablets by mouth for a period of 32 months.

Debbie Griffin

Elisabeth Laundy

Neptune National Institutes of Health, NIDDK, Nephcure Kidney International, University of Michigan The purpose of this multi-center, observational research study is to learn more about four diseases which cause nephrotic syndrome: Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN) and Alport syndrome. By collecting health information and laboratory samples from individuals who have these diseases and by making this information available to researchers, we hope to gain new knowledge about these diseases and to find better treatments for them.
  • Length: Participation lasts for 3 years. During the first year, there are 4 study visits. There are two study visits in year 2 and in year 3. When possible, study visits are scheduled to coincide with regularly scheduled clinic appointments.
  • Time commitment: approximately one hour per visit. Patients are seen at enrollment and at 4-6 month intervals. Visits are in-person and by telephone. When possible, study visits are scheduled to coincide with regularly scheduled clinic appointments.
  • Procedures: Blood and urine samples, kidney tissue (only if a biopsy is already being done) and various types of information are obtained from participants.
    Biospecimens are stored in biorepositories and are made available to researchers for approved research studies.
  • Eligibility: age 18 - 79, patients with Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease, Membranous Nephropathy and Alport syndrome may be eligible

Cathy Creed

Elisabeth Laundy

Cognitive Impairment KUMC Kidney Institute Evaluation of the changes in memory and thinking before and after transplant in relation to changes seen in images of the brain
  • Length: 1-2 years
  • Time commitment: 1-2 visits pre-transplant, and 2 visits prost-transplant to complete assessments
  • Procedures: Memory assessments, brain MRI, collection of blood and urine, medical history, and questionnaires
  • Eligibility: age 25-70, pre-transplant ESRD patients listed for renal transplantation at KU

Sean Obrien

Jessica Wilson

EPOC PKD NIH This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), The long-term goal is to develop new knowledge of biomarkers that indicate changes in the disease progression. An understanding of biomarkers will benefit PKD patients as new therapies are being developed and tested.
  • Length: 5 years
  • Time commitment: Two hours once per year
  • Procedures: MRI, blood and urine labs, and questionnaires
  • Eligibility: age 4-35, with early stage PKD, and normal kidney function

Cathy Creed

Elisabeth Laundy

Debbie Griffin

FALCON REATA FALCON is a Phase 3 clinical study evaluating the effectiveness and safety of bardoxolone methyl (an oral investigational drug) in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
  • Length: 2 years
  • ime commitment: 24 visits over 2 years, each visit is one to two hours in length
  • Procedures: EKG, Echocardiogram, physical exams, collection of blood and urine, medical history, and questionnaires
  • Eligibility: age 18 - 69

Cathy Creed

Elisabeth Laundy

Debbie Griffin

Fabry Registry Genzyme Collection of clinical data on patients with Fabry disease around the world in an effort to help health professionals involved in treatment or diagnosis better understand Fabry Disease and its management
  • Length: Indefinitely
  • Time commitment: Data will be obtained from medical record. 30 minutes or less phone call if additional information needed
  • Procedures: Questionnaires
  • Eligibility: Diagnosed with Fabry Disease
Debbie Griffin
Renal Tubular Function in Living Donors Investigator initiated Evaluate the renal tubular function pre- and post-nephrectomy in living donors.
  • The study will help to better understand the long-term effects of loss of nephrons on tubular function and injury in otherwise healthy humans. This will be a prospective trial where living donors will have renal function and tubular function checked before nephrectomy and at one year post-nephrectomy.

Sean Obrien

Jessica Wilson

Cognitive Function-Everolimus Novartis, llT Title: Alterations in Cognitive Function and Cerebral Blood Flow after Conversion from Calcineurin Inhibitors to Everolimus. This single center longitudinal 12 weeks observational study will determine whether conversion from calcineurin inhibitor (Tacrolimus) to an mTOR inhibitor, Everolimus, is associated with improvement in cognition and cerebral blood flow. 
  • Goal: Enroll 20 kidney transplant recipients who will undergo conversion and 10 matched controls at the University of Kansas Medical Center.

Sean Obrien

Jessica Wilson

PKD Registry KUMC Jared Grantham Kidney Institute The University of Kansas Medical Center is establishing a biorepository of blood and urine samples from adults with Polycystic Kidney Disease (PKD) in order to provide specimens to investigators for the discovery of biomarkers.

Biomarkers may help monitor PKD progression and determine the effectiveness of new treatments
  • Length: One Visit Only
  • Time commitment: One Hour
  • Procedures: fasting blood and urine collection, blood pressure, medical history questionnaire
  • Eligibility: diagnosed with PKD, age 18 – 70, have had an MRI or CT scan within the last 5 years

Cathy Creed

Casey Tan


Study Coordinator Contact Information

Cathy Creed, RN
ccreed@kumc.edu
(913) 588-0053

Sean Obrien
sobrien5@kumc.edu
(913) 574-0895

Jessica Wilson
jwilson12@kumc.edu
(913) 574-0894

Debbie Griffin, RN, CDE
dgriffin3@kumc.edu
(913) 588-7691

Elisabeth Laundy
elaundy@kumc.edu
(913) 588-8983

Casey Tan
ctan2@kumc.edu
(913) 574-3255

Internal Medicine

University of Kansas Medical Center
Internal Medicine
Nephrology & Hypertension Division
Mailstop 1022
3901 Rainbow Boulevard
Kansas City, KS 66160

Nephrology Fellowship
Transplant Fellowship

General Questions:
913-588-6048
Fellowship:
913-588-0486